Clinical trials: Cancer of Brain and Nervous System
Dementia, Dementia, Vascular
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Difficulty completing everyday tasks is a primary reason for the high cost of care, loss of caregiver paid hours, and general caregiver burden associated with dementia.
- Conditions
- Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed
- Trial name
- SmartPrompt (NCT04313582)
- Testing
- SmartPrompt smartphone application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Temple University
Cognitive/Functional Effects, Metastatic Cancer
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity
- Trial name
- NCT01372774
- Testing
- stereotactic radiosurgery, whole-brain radiation therapy
- Where
- 37 sites in United States
- Volunteers
- 194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Carcinoma, Esophageal Carcinoma
Defining Musical Toxicity and Its Effect on Patient Well-being
This study evaluates the experience of musicians who are going through cancer treatment.
- Conditions
- Breast Carcinoma, Esophageal Carcinoma, Head and Neck Carcinoma, Lung Carcinoma
- Trial name
- NCT06494046
- Testing
- Non-Interventional Study
- Where
- United States
- Sponsor
- Mayo Clinic
Brain Cancer, Central Nervous System Diseases
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply.
- Trial name
- NCT00805376
- Testing
- DNX-2401, Tumor Removal
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Tumor, Brain Tumor
Utility of Primary Glioblastoma Cell Lines
In this study, the characterization of human malignant glioma cell lines is described. After mechanical and enzymatic digestion of glioblastoma human biopsies from Neuromed IRCCS Neurosurgery patients, the investigators analyzed…
- Trial name
- NCT04180046
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Neuromed IRCCS
Lung Adenocarcinoma, Brain Metastases
Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases
The purpose of this study is to determine whether erlotinib plus pemetrexed, cisplatin are effective and safe in treating lung adenocarcinoma with brain metastases.
- Trial name
- NCT01578668
- Testing
- erlotinib, pemetrexed, cisplatin
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Guangzhou Medical University
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease).
- Trial name
- NCT05222620
- Testing
- Questionnaire Administration, Stereotactic Radiosurgery, Magnetic Resonance Imaging
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Brain and Central Nervous System Tumors
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00516282
- Testing
- CLORETAZINE, temozolomide
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Northwestern University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Neuroblastoma
A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain…
- Trial name
- NCT04253015
- Testing
- Data-collection
- Where
- 13 sites in Austria, France and 5 more
- Volunteers
- 125 people
- Sponsor
- RECORDATI GROUP
Diffuse Intrinsic Pontine Glioma
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
This phase I trial studies the side effects and best dose of temsirolimus when given together with vorinostat and with or without radiation therapy in treating younger patients with newly diagnosed or progressive diffuse…
- Trial name
- NCT02420613
- Testing
- Radiation Therapy, Temsirolimus, Vorinostat
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Irinotecan in Treating Children With Refractory Solid Tumors
This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Grade I Meningioma
- Trial name
- NCT00004078
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Children's Oncology Group
Primary Brain Tumor
Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients
To determine the safety of prophylaxis with Tinzaparin low molecular weight heparin in primary brain tumor patients. 2. To determine the incidence of deep venous thrombosis or pulmonary embolism in brain tumor patients who will…
- Trial name
- NCT00629447
- Testing
- Innohep
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Duke University
Central Nervous System Diseases
Dexmedetomidine for Prevention of Postoperative Delirium After Intracranial Operation for Brain Tumor
Postoperative delirium is common after major surgery, and is associated with adverse outcomes. Systematic reviews and meta-analyses of randomized controlled trials have shown that perioperative administration of dexmedetomidine…
- Trial name
- DEPOD (NCT04399343)
- Testing
- Dexmedetomidine, Normal saline
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Capital Medical University
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive decline in patients with cancer that has spread from the primary site…
- Conditions
- Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
- Trial name
- NCT02360215
- Testing
- Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
- Where
- 220 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- NRG Oncology
Primary Brain Tumor, Epilepsy
Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery
The purpose of this study is to determine the feasibility, efficacy and safety of intravenous and oral antiepileptic treatment with levetiracetam in patients with primary brain tumors and symptomatic epilepsy in the period of…
- Trial name
- NCT00571155
- Testing
- levetiracetam
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in patients with advanced cancers - melanoma, lung, breast and glioblastoma multiforme (GBM) involving the CNS during…
- Trial name
- DM-CHOC-PEN (NCT02038218)
- Testing
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- DEKK-TEC, Inc.
Brain and Central Nervous System Tumors
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00387933
- Testing
- hydroxyurea, imatinib mesylate, vatalanib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.